By Exec Edge Editorial Staff RBC Capital analyst Shagun Singh maintained Zynex, Inc. (Nasdaq:ZYXI) with an outperform rating and raised its price target from $13 to $15. Meanwhile, HC Wainwright & Co. analyst Yi Chen maintained a buy rating and...

By Daniella Parra FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue was $144.9 million and a reclassification negatively impacted net revenues by $4.7 million. Gross margin was 67.5%, a decrease of 70 basis points and operating expenses were $83.6...

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which...

By Karen E. Roman Portillo’s Inc. (NASDAQ: PTLO), the casual restaurant known for its Chicago-style favorites menu, reported a 24.5% increase in total revenue for the last quarter of 2023 and a rise of 4.4% on same-restaurant sales. Operating income...

Exec Edge interviewed WHY Brands Inc. Founder and CEO Steven Dunn, Chief Brand Officer & Creative Officer Diana Barnes WHY has been transforming itself into a house of brands including Munchkin, Curio Dunn and Ms. Barnes co-founded lifestyle products company...

By Daniella Parra Agilent Technologies, Inc. (NYSE: A) announced Padraig McDonnell, president of the Agilent CrossLab Group (ACG), as CEO-elect and chief operating officer, succeeding Mike McMullen, the current President and CEO, who will retire. Agilent said McDonnell has held...

  By Karen E. Roman Planet Fitness, Inc. (NYSE: PLNT) reported total revenue grew 1.4% on the fourth quarter to $285.1 million and system-wide same store sales rose 7.7%. Adjusted EBITDA grew 7.8% to $114.3 million from $106.1 million the...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting...

By Daniella Parra Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure. Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments...

IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Jeffrey Jakubiak, partner at Vinson & Elkins. Mr. Jakubiak spoke to Editor-in-Chief John Jannarone about the company’s forecast for 2024 regarding the FERC’s decisions...